Home / Expertise / Life Sciences & Healthcare
Lab

Life Sciences & Healthcare

Czech Republic

Our Prague team regularly advises pharmaceutical companies and medical device manufacturers on a range of commercial and regulatory issues.

We work with and have established long-term relationships with the top 100 lifesciences companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our lifesciences teams in Central and Eastern Europe advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your lifesciences business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

Read more Read less

Feed

Show only
1 July 2020
Sign­ing with e-sig­na­ture in CEE
This guide fo­cuses on the most im­port­ant leg­al areas where elec­tron­ic sig­na­tures are usu­ally used: em­ploy­ment law, com­mer­cial con­tracts, real es­tate law, cor­por­ate law and bank­ing and fin­ance con­tracts. This guide ad­di­tion­ally in­cludes help­ful at-a-glance
20 April 2020
CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
Are you look­ing for in­form­a­tion on phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising? Learn more about it in this CMS Ex­pert Guide.
08 July 2020
“WIPO PROOF”: WIPO’s new on­line ser­vice which helps in­nov­at­ors and cre­at­ors...
The World In­tel­lec­tu­al Prop­erty Or­gan­isa­tion (WIPO) re­cently launched its new on­line busi­ness ser­vice, “WIPO PROOF”. The plat­form aims to help in­nov­at­ors and cre­at­ors safe­guard their in­tel­lec­tu­al...
30 October 2019
CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s...
CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion of Al­vo­gen’s CEE busi­ness. Find out more.
20 April 2020
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
Are you look­ing for in­form­a­tion on can­nabis law and le­gis­la­tion? This CMS Ex­pert Guide provides you with everything you need to know.
02 July 2020
EU agrees new class ac­tion re­gime for con­sumer dis­putes
After a long gest­a­tion, on 30 June 2020 the Coun­cil of the EU pub­lished the text for the col­lect­ive re­dress dir­ect­ive (the “CR Dir­ect­ive”) (text avail­able here). This le­gis­la­tion is in­ten­ded to bet­ter...
26 May 2020
European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
22 May 2020
For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
04 May 2020
EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
30 April 2020
USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...
17 April 2020
Is a pri­vacy-friendly use of mo­bile ap­plic­a­tions to com­bat COV­ID-19 our...
A Pan-European Ap­proach to the Use of Mo­bile Apps and Mo­bile Data With its Re­com­mend­a­tion of 8 April 2020 on steps and meas­ures to de­vel­op a com­mon ap­proach to the use of mo­bile ap­plic­a­tions and mo­bile...
06 April 2020
Czech drug au­thor­ity re­com­mend­a­tions on clin­ic­al tri­als
The Czech State In­sti­tute for Drug Con­trol (SUKL) re­cently pub­lished its opin­ion on on­go­ing clin­ic­al tri­als and clin­ic­al tri­als that have not yet star­ted in light of the COV­ID-19 situ­ation. With the ex­cep­tion...